Evidence map›Paper›PMID 37337279›Full record

ArticleActa neuropathologica communications2023

Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy.

Tristan Williams, Tim Bathe, Quan Vo, Patricia Sacilotto, Karen McFarland, Alejandra Jolie Ruiz, Gabriela P Hery, Patrick Sullivan, David R Borchelt, Stefan Prokop and 1 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Tristan WilliamsCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Tim BatheCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Quan VoCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Patricia SacilottoCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Karen McFarlandCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Alejandra Jolie RuizCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Gabriela P HeryCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Patrick SullivanDepartment of Medicine, Duke University, Durham, NC, 27710, USA.
David R BorcheltCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Stefan ProkopCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.
Paramita ChakrabartyCenter for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA. pchakrabarty@ufl.edu.ORCID 0000-0002-6226-3776
University of Florida · USDuke University · USEli Lilly (United States) · USUniversity of Florida Health · US

Funding

Social Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI Rosie E Curiel Cid · 2020 to 2026
$25.6M
APOE as a modifier of prion-like spread in dementiaRF1AG057933 · NIA · UNIVERSITY OF FLORIDA · PI BORCHELT, DAVID R, CHAKRABARTY, PARAMITA · 2018 to 2018
$2.6M
Towards understanding the role of immune regulation of Apolipoprotein E function in Alzheimer's disease proteostasisR01AG055798 · NIA · UNIVERSITY OF FLORIDA · PI CHAKRABARTY, PARAMITA · 2017 to 2022
$1.9M
Clinical and Translational Predoctoral training in Alzheimers Disease and Related DementiasT32AG061892 · NIA · UNIVERSITY OF FLORIDA · PI PARAMITA CHAKRABARTY, JADA M LEWIS · 2018 to 2026
$1.8M
NIA NIH HHS P30 AG066506NIA NIH HHS R01 AG055798NIA NIH HHS RF1 AG057933NIA NIH HHS T32 AG061892
6 · The paper itself

Abstract

Apolipoprotein (APOE) E4 isoform is a major risk factor of Alzheimer's disease and contributes to metabolic and neuropathological abnormalities during brain aging. To provide insights into whether APOE4 genotype is related to tau-associated neurodegeneration, we have generated human P301S mutant tau transgenic mice (PS19) that carry humanized APOE alleles (APOE2, APOE3 or APOE4). In aging mice that succumbed to paralysis, PS19 mice homozygous for APOE3 had the longest lifespan when compared to APOE4 and APOE2 homozygous mice (APOE3 > APOE4 ~ APOE2). Heterozygous mice with one human APOE and one mouse Apoe allele did not show any variations in lifespan. At end-stage, PS19 mice homozygous for APOE3 and APOE4 showed equivalent levels of phosphorylated tau burden, inflammation levels and ventricular volumes. Compared to these cohorts, PS19 mice homozygous for APOE2 showed lower induction of phosphorylation on selective epitopes, though the effect sizes were small and variable. In spite of this, the APOE2 cohort showed shorter lifespan relative to APOE3 homozygous mice. None of the cohorts accumulated appreciable levels of phosphorylated tau compartmentalized in the insoluble cell fraction. RNAseq analysis showed that the induction of immune gene expression was comparable across all the APOE genotypes in PS19 mice. Notably, the APOE4 homozygous mice showed additional induction of transcripts corresponding to the Alzheimer's disease-related plaque-induced gene signature. In human Alzheimer's disease brain tissues, we found no direct correlation between higher burden of phosphorylated tau and APOE4 genotype. As expected, there was a strong correlation between phosphorylated tau burden with amyloid deposition in APOE4-positive Alzheimer's disease cases. Overall, our results indicate that APOE3 genotype may confer some resilience to tauopathy, while APOE4 and APOE2 may act through multiple pathways to increase the pathogenicity in the context of tauopathy.

Indexed as

Alzheimer DiseaseTauopathiesAnimalsApolipoprotein E2Apolipoprotein E3Apolipoprotein E4Apolipoproteins EGenotypeHumansLongevityMiceMice, TransgenicApolipoprotein E2Apolipoprotein E3Apolipoprotein E4Apolipoproteins EAgingAPOEImmune responsePhosphorylated tauSurvival

Identifiers

PMID37337279
PMCPMC10280946
OpenAlexW4381251174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.